Brookdale Senior Living
BKD
$11.90
+0.93%
Brookdale Senior Living, Inc. is the largest operator of senior living communities in the United States, providing independent living, assisted living, memory care, and continuing care retirement communities. The company generates revenue primarily through resident fees and management fees, with a focus on serving the aging population. Brookdale has been undergoing a strategic transformation to improve occupancy and operational efficiency, while managing a high debt load and recent quarterly losses. Investor attention is centered on the company's ability to sustain revenue growth, achieve profitability, and reduce leverage in a challenging operating environment.…
BKD
Brookdale Senior Living
$11.90
Investment Opinion: Should I buy BKD Today?
Rating: Buy. The thesis is that Brookdale is undervalued on a price-to-sales basis (0.81x vs. historical 1.5-2.0x) and has strong analyst support (Strong Buy, average target $19.25, +64% upside) despite near-term operational challenges. The company's scale as the largest senior living operator provides a competitive moat, and recent analyst upgrades suggest improving sentiment.
Sign up to view all
BKD 12-Month Price Forecast
The AI assessment leans bullish due to the compelling valuation and analyst support, but confidence is medium given the operational challenges. The key swing factor is whether Brookdale can reverse the revenue decline and achieve profitability. If the company delivers a strong Q2 2026 with revenue growth and narrowing losses, the stock could rally toward the $19-23 range. Conversely, another quarter of revenue decline would likely push the stock toward the bear case. The stance would be upgraded to high confidence if revenue growth resumes and net losses turn to profits; downgraded to neutral if revenue continues to decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Brookdale Senior Living's 12-month outlook, with a consensus price target around $19.25 and implied upside of +61.8% versus the current price.
Average Target
$19.25
0 analysts
Implied Upside
+61.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $23
Analyst target range
Brookdale is covered by 6 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.33). The average target price is $19.25, implying an upside of +64.2% from the current price of $11.72. The target range is $17.00 to $23.00, with the low target still representing a 45% upside, indicating that analysts are broadly bullish on the stock's recovery potential. Recent ratings actions include upgrades from B of A Securities (from Underperform to Buy) and Barclays (from Equal Weight to Overweight), reflecting improving sentiment. The wide spread between low and high targets suggests moderate uncertainty, but the overall bullish stance points to expectations of operational improvement and margin expansion.
Bulls vs Bears: BKD Investment Factors
Brookdale presents a classic turnaround story with strong analyst support but significant operational and financial hurdles. The bull case rests on a compelling valuation (PS 0.81x), a Strong Buy consensus with 64% upside, and improving analyst sentiment. However, the bear case highlights persistent losses, declining revenue, and high leverage, which could derail the recovery. The most critical tension is whether the company can achieve the earnings recovery implied by its forward PE of 68.9x; if it fails, the stock could fall toward its 52-week low of $7.29. Currently, the evidence slightly favors the bulls given the low PS ratio and analyst upgrades, but the risk is substantial.
Bullish
- Analyst Strong Buy with 64% upside: Consensus rating is Strong Buy (1.33) with an average target of $19.25, implying +64.2% upside from $11.72. Even the low target of $17.00 offers +45% upside, reflecting broad analyst optimism.
- Undervalued on price-to-sales: PS ratio is 0.81x, well below the historical average of 1.5-2.0x seen in 2024-2025. This suggests the market is pricing in significant operational challenges, but also provides a margin of safety if the company stabilizes.
- Strong 1-year price performance: Stock is up +53.4% over the past year, outperforming the S&P 500's +18.6% gain. This indicates improving investor sentiment and successful execution of strategic initiatives despite recent pullback.
- Improving analyst sentiment: Recent upgrades from B of A Securities (Underperform to Buy) and Barclays (Equal Weight to Overweight) signal growing confidence in the company's recovery. These actions often precede sustained price appreciation.
Bearish
- Revenue declining year-over-year: Q1 2026 revenue was $764.9M, down -1.95% YoY, breaking a trend of modest growth. This stagnation raises concerns about organic growth and competitive pressures in the senior living market.
- Persistent net losses: The company reported a net loss of -$6.9M in Q1 2026, continuing a streak of quarterly losses. Trailing EPS is -$0.10, and the net margin is -8.4%, indicating ongoing profitability challenges.
- High leverage and negative equity: Debt-to-equity is -148.9x, reflecting negative shareholder equity. This high leverage increases financial risk and limits financial flexibility, especially if interest rates remain elevated.
- Expensive forward valuation: Forward PE is 68.9x, implying the market expects a massive earnings recovery. If the company fails to meet these expectations, the stock could face significant de-rating.
BKD Technical Analysis
Brookdale's stock has exhibited a strong recovery over the past year, with a 1-year price change of +53.4%, significantly outperforming the S&P 500's +18.6% gain. However, the current price of $11.72 sits at only 68.6% of the 52-week range (low $7.29, high $17.09), indicating a substantial pullback from the highs. This positioning suggests that while the long-term trend has been upward, the stock is currently in a corrective phase, trading closer to the lower end of its range, which could present either a value opportunity or signal further downside risk.
Beta
0.61
0.61x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$7-$17
Price range past year
Annual Return
+54.5%
Cumulative gain past year
| Period | BKD Return | S&P 500 |
|---|---|---|
| 1m | -18.5% | +2.0% |
| 3m | -2.9% | +1.0% |
| 6m | -19.2% | +11.8% |
| 1y | +54.5% | +18.1% |
| ytd | +9.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BKD Fundamental Analysis
Revenue in Q1 2026 was $764.9 million, a slight decline of 1.95% year-over-year, breaking a trend of modest growth seen in prior quarters (e.g., Q2 2025 revenue was $812.9 million, Q3 2025 $777.8 million). The company's revenue has been relatively stable but is showing signs of stagnation, with the most recent quarter missing the prior year's figure. The assisted living and memory care segment remains the primary driver, but management fees and reimbursement costs contribute marginally. This flat revenue trajectory raises concerns about the company's ability to grow organically in a competitive market.
Quarterly Revenue
$764856000.0B
2026-03
Revenue YoY Growth
-1.9%
YoY Comparison
Gross Margin
3.3%
Latest Quarter
Free Cash Flow
$9322000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BKD Overvalued?
Given that Brookdale has negative trailing earnings (net income of -$6.9 million in Q1 2026), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 0.81x, which is below the historical average of around 1.5x-2.0x seen in 2024-2025, indicating a potential undervaluation. However, the forward PE ratio of 68.9x suggests that the market expects a significant earnings recovery, as analysts project EPS of $0.455 for the next fiscal year. This implies a high growth expectation, which may be optimistic given the recent revenue decline.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are prominent for Brookdale. The company has negative shareholder equity (debt-to-equity of -148.9x), indicating a highly leveraged balance sheet. Interest expenses were $60.9M in Q1 2026, consuming a significant portion of EBITDA ($127.0M). The company has posted net losses for eight consecutive quarters, with a cumulative net loss of -$400M over the past two years. Free cash flow is barely positive at $9.3M TTM, limiting the ability to service debt or invest in growth. Revenue concentration in the assisted living and memory care segment adds operational risk, as occupancy and pricing pressures directly impact profitability.
FAQ
The key risks are: 1) Financial risk: high leverage (debt-to-equity -148.9x) and persistent net losses (-$6.9M in Q1 2026) could lead to liquidity issues. 2) Operational risk: revenue declined -1.95% YoY, and if this continues, it could impair the company's ability to service debt. 3) Market risk: the stock is volatile (beta 0.609) and has underperformed the S&P 500 over the past month (-21.1% vs +5.5%). 4) Execution risk: the forward PE of 68.9x implies high expectations; any miss could trigger a sharp selloff. The most severe risk is a debt restructuring scenario, which could wipe out equity holders.
Analysts have a Strong Buy consensus with an average target of $19.25, implying 64% upside. The bull case (30% probability) targets $19.25-$23.00, driven by successful operational turnaround. The base case (45% probability) targets $17.00-$19.25, assuming gradual improvement. The bear case (25% probability) targets $7.29-$11.72, if operational challenges persist. The most likely scenario is the base case, where revenue stabilizes and losses narrow, leading to a stock price around $19.25 within 12 months.
Based on price-to-sales, BKD appears undervalued at 0.81x, compared to its historical range of 1.5-2.0x. However, the forward PE of 68.9x suggests the market expects a massive earnings recovery, which could be optimistic given the recent revenue decline. The stock is trading at a discount to its historical valuation, but the high forward PE indicates that the market is pricing in significant future growth. Overall, the stock is undervalued on a sales basis but may be fairly valued or even overvalued on an earnings basis if the recovery fails to materialize.
BKD is a good buy for investors with a high risk tolerance and a long-term horizon. The stock is trading at a PS ratio of 0.81x, well below its historical average, and analysts have a Strong Buy consensus with an average target of $19.25, implying 64% upside. However, the company is currently loss-making and has high leverage, so the risk is substantial. If you believe in the operational turnaround and can withstand volatility, it could be a rewarding investment. For conservative investors, it may be better to wait for evidence of sustained revenue growth and profitability.
BKD is more suitable for long-term investment (3-5 years) given its turnaround nature and high volatility. The stock has a beta of 0.609, indicating lower correlation to the market, but it has experienced significant price swings (52-week range $7.29-$17.09). Short-term trading is risky due to the recent -21% monthly decline and uncertainty around earnings. For long-term investors, the potential for operational improvement and the aging demographic tailwind could provide substantial returns. A minimum holding period of 3 years is recommended to allow the turnaround to play out.